DOCSLIB.ORG

Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0224193 A1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0224193 A1 US 20190224193A1 ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2019 /0224193 A1 REID et al. ( 43 ) Pub . Date: Jul. 25 , 2019 ( 54 ) COMPOSITIONS OF NATURAL EXTRACTS A61K 36 / 00 ( 2006 .01 ) AND USE THEREOF IN METHODS FOR A61K 31/ 122 ( 2006 .01 ) PREVENTING OR TREATING DISEASES A61K 38 /06 ( 2006 .01 ) ( 71) Applicant: Christopher Brian REID , (US ) A61K 31 /4164 ( 2006 .01 ) A61K 31 /375 (2006 . 01) ( 72 ) Inventors : Christopher Brian REID , Los A61K 31 / 355 ( 2006 .01 ) Angeles , CA (US ); Que T . Collins, A61K 31/ 12 Santa Monica , CA (US ) ( 2006 .01 ) 2 ) U . S . CI. (21 ) Appl . No .: 16 / 134 , 723 CPC .. .. .. .. A61K 31/ 496 (2013 . 01 ) ; A61K 45 / 06 (2013 .01 ) ; A61K 31/ 327 (2013 .01 ) ; A61K (22 ) Filed : Sep . 18 , 2018 31/ 194 ( 2013. 01 ) ; A61K 38 / 1816 ( 2013 .01 ) ; Related U . S . Application Data A61K 36 /00 (2013 .01 ) ; YO2A 50 / 389 (60 ) Continuation of application No . PCT /US2017 / (2018 .01 ) ; A61K 38/ 063 ( 2013 . 01 ) ; A61K 033234 , filed on May 18 , 2017 , Continuation of 31/ 4164 (2013 . 01 ) ; A61K 31/ 375 (2013 . 01 ) ; application No . 16 / 039 , 134 , filed on Jul. 18 , 2018 , A61K 31/ 355 ( 2013. 01 ) ; A61K 31/ 12 which is a division of application No. 15 / 241, 308 , ( 2013 .01 ) ; A61K 31 /122 (2013 .01 ) filed on Aug. 19 , 2016 , now abandoned , which is a division of application No . 13 /815 ,664 , filed on Mar . 14 , 2013 , now abandoned . (57 ) ABSTRACT (60 ) Provisional application No . 62 / 390 , 081, filed on Mar. 18 , 2016 , now abandoned , provisional application No. 62 /390 , 438 , filed on Mar. 29 , 2016 . A composition for reducing miR -3120 expression in a cell or tissue of a subject comprises at least one oil or extract Publication Classification selected from a group comprising an orange , frankincense ( 51 ) Int. Ci. and cannabis oil or extract. A method for reducing miR -3120 A61K 31/ 496 ( 2006 . 01 ) expression in a cell or tissue of a subject comprises admin A61K 45 / 06 ( 2006 .01 ) A61K 31/ 327 ( 2006 .01 ) istering to the subject a composition comprising at least one A61K 31 / 194 ( 2006 .01 ) oil or extract selected from the group comprising an orange , A61K 38 / 18 ( 2006 .01 ) frankincense and cannabis oil or extract . Patent Application Publication Jul . 25, 2019 Sheet 1 of 21 US 2019 /0224193 A1 0000000 0 000000000 th YA wood HRANU conoscononwowoso MW 9999999999 . ww oooooooooooooo 9999999999999999999999999999999999999999999999999999999 o WWWWWWWWWWWWWWWWWWWWWWWWWWWWW Patent Application Publication Jul . 25, 2019 Sheet 2 of 21 US 2019 /0224193 A1 IniVE P 5 Woossono Patent Application Publication Jul . 25, 2019 Sheet 3 of 21 US 2019 /0224193 A1 2progedoop nnnn 0000000000000000000000 \000000000 VOONIX ODDOD)DDOODDODO DODDODODDAODDODDD DDDDLDODD 1000ODOOODDOD ODO OOOIon DDODIDOhOODDOJDODODD Im DDODDY OOODO ODYNODOD Patent Application Publication Jul . 25, 2019 Sheet 4 of 21 US 2019 /0224193 A1 XX X X good . esse W OR Patent Application Publication Jul . 25, 2019 Sheet 5 of 21 US 2019 /0224193 A1 ' , ' ' , ' s .. .. ' ' , ' ' , ' ' , ' ' , ' ' , '. ' .: : .: * . :* :u. U. 111111111111111 17 . Fig . 8A Patent Application Publication Jul . 25, 2019 Sheet 6 of 21 US 2019 /0224193 A1 ok . * * * * * * * * * * * * * * * * * * 1. www * .! * S 20 * Fig . 8B Patent Application Publication Jul . 25, 2019 Sheet 7 of 21 US 2019 /0224193 A1 . : . : : . : Patent Application Publication Jul . 25, 2019 Sheet 8 of 21 US 2019 /0224193 A1 Patent Application Publication Jul. 25 , 2019 Sheet 9 of 21 US 2019 /0224193 A1 ws Patent Application Publication Jul. 25 , 2019 Sheet 10 of 21 US 2019 /0224193 A1 iii. .: H 888888888 Patent Application Publication Jul. 25 , 2019 Sheet 11 of 21 US 2019 /0224193 A1 -DO NCOT + lemon 48 hours3 * * * * * * X Patent Application Publication Jul . 25, 2019 Sheet 12 of 21 US 2019 /0224193 A1 . 373 cells * 1. week S OX *** * * * titi WWWWW * * Patent Application Publication Jul. 25 , 2019 Sheet 13 of 21 US 2019 /0224193 A1 00000 So * * * * * * * * * OOOOOOO Patent Application Publication Jul. 25 , 2019 Sheet 14 of 21 US 2019 /0224193 A1 =O0 * Patent Application Publication Jul. 25 , 2019 Sheet 15 of 21 US 2019 /0224193 A1 313 cells + 2 weeks 10 % ODClove 1 :5000 * 0 . 000000 20 DieWooLOS 00000 2 S WW w OMOS Patent Application Publication Jul. 25 , 2019 Sheet 16 of 21 US 2019 /0224193 A1 w % % % 0200 888888 www Patent Application Publication Jul . 25, 2019 Sheet 17 of 21 US 2019 /0224193 A1 . : . : .: : . : . : . : . : . : . : .: . : . : . : . : .: : . : . : . : . : .: : . : . : . :. : . : . : .: :. :. : . : . : .: . : . : . : . : . : . : . : . : . : . : . : . : .: :. : . : . : . : . : . : . : . : . : .: : . : .: . : . : . : . : . : . : . : . : . : . : . : . : . : . : . : . : . : . : . : . : . : . : . : . : . : . : . : . :. : . :. : . : . : .: : : : : sriririririr : .rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr : * : : . : . : .', . :. :RIA ** ** S . ,'.. *** ** * * *** * . ,.. : ,1 . .', . i i '., i . '.,ii ** *** * * . : . : . : . : . : . : . : . : . : . : . : . : . : . : . : . : . : . : . : . Fig . 18 juared uogie?yjddy uogie?giqnd n ‘ ST “ 6107 jaa4S 81 JO 17 SA 6107/ E6IH770 IV . ' . ' . ' . ' . ' . ' . ' . ' , ' ' ' ' , ' , ' , ' , " " " " " " " , " " * ' , ' ' , ' ' , ' ' , ' ' , ' 1 ' , ' , ' ' , ' ' , , ' ' , ' ' , ' ' ' ' , ' ' ' ' . ' . * * DI 61 Patent Application Publication Jul . 25, 2019 Sheet 19 of 21 US 2019 /0224193 A1 * * * * * * * * * * * * * * * * * * ** * * * * * * * Middl prantita Ok Photo * * * * * * * * * * * * * * * * '. .: Ceratiche Senaire Enligen reddito Prixi boutriton Puhay : Romantika Asorb Essa para Must Dens: VOISTA y unpol .:iciri wanhamini tai baxxix * * Login F40PS & st: exp? asly '. Itsbrgs TELAS Draka : . MahontalUsurton . leac Ejasyrien . A Clara drendelig . Andrer sigasig ** RN .' .: . Pagatorepeatar . VaRdespiti .: * * daysphalustat 68 linging 2 :. '. ???? Film : . Coro . .. 3 D r Sigralma .: Gdexin Cork : Una untk Stadion gestos : Micro 190 : ipaie Nantonalego . Ormoran keplexion : : : Dirs aurkotusto : 1it kloria Unitslocs grokin spores androFerdroix ??er2: { 4 } ; ? :! ! ! Finle ETAG ADAM S : WORMWADIN ER Sosire Kopar by logga Oreport Regulier Recombination SumwWotetor Schin Otokkan sigrating KuideEau KEPIK u wewe Iwertszcialin Semaine rtg ( F # skilning N . dobila Dodows Juzwalwidow -YATDOX Toni Coup urg aostons Kopuzan . 18 ce taukis Alevtan Faily protected Thoxerem ban FisingFolxxis Berekek win Pelo Por signing Exch ep :n Eurzydkaa kequor FOXWK 3 * * Einhrocesin Sensing am signaling Flipony Votive deve RAY Sighting Meros mesilho . .. asa : : : . Fig . 20 Patent Application Publication Jul. 25, 2019 Sheet 20 of 21 US 2019 /0224193 A1 . : : : : : : : : :: : : :: : . XX :: : : : : : : : :: . : XXX . : · . TUTTIIIIII . Fig . 21 Patent Application Publication Jul. 25 , 2019 Sheet 21 of 21 US 2019 /0224193 A1 ANGIS. CES _ ut : . 102 genes 2015 - 121103 :40 * Ceviana Mud3 ,5 _ 1829ra 2015 -12 - 11 0 :45 AM . : : : : : :: : : :: : : : : : : :: : . " . .. .. .. is . is . '. .. boggande . & CSKER Ozo: BuspiadyDisaa organsmainjuryandnerylties ReproductiveSysturoDisesse DarrumartalDcorder correchteTisuesadeos HlyrilyDisease InfanátoryResponses crostismalFunctions Cardiovascuassease Conditions IrromerialzgierDizonte SachsintestinaDiscover CausaCevapant SelitalandHis DermacmacalDiseases . 69.6K EncoursSaturnDisorder's Hercogical065038 CalDeathardSuvi CelularNow HeldugulOscar Fordwagic.Dissrilers CelMarpulagy curoorphalaga (4):????fiedProlforation ärgsrixnalownia Wolphalic SueReveliones FinalandVioozcaOseae ServousSystemDavecprant*dFunciar KesicySYKETS. ??arryinati???,?R.ap4" aispratnm. HanatslogiexSystem: opritarnicDiseaze doovelaprent: (44&f4141\¢{" -cellsignalingandIrizacion BellularFurtivismeMaintanganco DevebprmenyandFunctozi irfraOsease DavebportandFurultay TisswxFlorpleegy DNARecor, Cabedisiawabolin Respums Herstopoless HungaryRepone Lypagiliigstueue Orgorization SruaKatecueRechenzory celm . anDicose AuditoryDisease CallScudno GanzEpoiD q???????rt CoinciveTissueDivolosantindFunction ReproductiveŠyetanDavespmentandFunctan FCArdkartulim DigestveSygeDevelopmentandFunction Heal25DevelopineandFundben HegotiaS OaxsoomentOrgaismal HerandShinOslopmen :Fordi FrioRadioScavenging wavelallerFUN Fig . 22 US 2019 /0224193 A1 Jul. 25 , 2019 COMPOSITIONS OF NATURAL EXTRACTS SUMMARY OF THE INVENTION AND USE THEREOF IN METHODS FOR [ 0005 ] Virtually all patients could benefit from novel, PREVENTING OR TREATING DISEASES efficacious drug compositions. The present invention pro vides novel orange , frankincense , cannabis and other natural CROSS REFERENCE TO RELATED oil and extract related compositions and inexpensive drug APPLICATIONS compositions for preventing and / or treating various condi [0001 ] This application is a continuation of PCT/ US2017 / tions, diseases , and maladies especially metabolic diseases 033234 , filed May 18 , 2017 , which claims priority to U . S . and disorders, cancer, psoriasis and improving health and Provisional Patent App . No . 62 /390 , 081, filed Mar. 18 , 2016 , well -being in general. The present invention also provides and U . S . Provisional Patent App . No . 62 /390 ,438 , filed Mar . corresponding methods for producing such compositions 29 , 2016 ; and is a continuation of U . S . patent application and methods of preventing a condition , disorder or disease Ser . No . 16 / 039, 134 , filed Jul. 18 , 2018 , which is a divisional and treating a condition , disorder or disease in an animal or of Ser. No. 15 /241 , 308 filed Aug . 19 , 2016 , which is a human
Load more

Recommended publications
  • Strategies to Increase ß-Cell Mass Expansion
    This electronic thesis or dissertation has been downloaded from the King’s Research Portal at https://kclpure.kcl.ac.uk/portal/ Strategies to increase -cell mass expansion Drynda, Robert Lech Awarding institution: King's College London The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without proper acknowledgement. END USER LICENCE AGREEMENT Unless another licence is stated on the immediately following page this work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ You are free to copy, distribute and transmit the work Under the following conditions: Attribution: You must attribute the work in the manner specified by the author (but not in any way that suggests that they endorse you or your use of the work). Non Commercial: You may not use this work for commercial purposes. No Derivative Works - You may not alter, transform, or build upon this work. Any of these conditions can be waived if you receive permission from the author. Your fair dealings and other rights are in no way affected by the above. Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 02. Oct. 2021 Strategies to increase β-cell mass expansion A thesis submitted by Robert Drynda For the degree of Doctor of Philosophy from King’s College London Diabetes Research Group Division of Diabetes & Nutritional Sciences Faculty of Life Sciences & Medicine King’s College London 2017 Table of contents Table of contents .................................................................................................
    [Show full text]
  • The Rise and Fall of the Bovine Corpus Luteum
    University of Nebraska Medical Center DigitalCommons@UNMC Theses & Dissertations Graduate Studies Spring 5-6-2017 The Rise and Fall of the Bovine Corpus Luteum Heather Talbott University of Nebraska Medical Center Follow this and additional works at: https://digitalcommons.unmc.edu/etd Part of the Biochemistry Commons, Molecular Biology Commons, and the Obstetrics and Gynecology Commons Recommended Citation Talbott, Heather, "The Rise and Fall of the Bovine Corpus Luteum" (2017). Theses & Dissertations. 207. https://digitalcommons.unmc.edu/etd/207 This Dissertation is brought to you for free and open access by the Graduate Studies at DigitalCommons@UNMC. It has been accepted for inclusion in Theses & Dissertations by an authorized administrator of DigitalCommons@UNMC. For more information, please contact [email protected]. THE RISE AND FALL OF THE BOVINE CORPUS LUTEUM by Heather Talbott A DISSERTATION Presented to the Faculty of the University of Nebraska Graduate College in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy Biochemistry and Molecular Biology Graduate Program Under the Supervision of Professor John S. Davis University of Nebraska Medical Center Omaha, Nebraska May, 2017 Supervisory Committee: Carol A. Casey, Ph.D. Andrea S. Cupp, Ph.D. Parmender P. Mehta, Ph.D. Justin L. Mott, Ph.D. i ACKNOWLEDGEMENTS This dissertation was supported by the Agriculture and Food Research Initiative from the USDA National Institute of Food and Agriculture (NIFA) Pre-doctoral award; University of Nebraska Medical Center Graduate Student Assistantship; University of Nebraska Medical Center Exceptional Incoming Graduate Student Award; the VA Nebraska-Western Iowa Health Care System Department of Veterans Affairs; and The Olson Center for Women’s Health, Department of Obstetrics and Gynecology, Nebraska Medical Center.
    [Show full text]
  • Funktionelle in Vitro Und in Vivo Charakterisierung Des Putativen Tumorsuppressorgens SFRP1 Im Humanen Mammakarzinom
    Funktionelle in vitro und in vivo Charakterisierung des putativen Tumorsuppressorgens SFRP1 im humanen Mammakarzinom Von der Fakult¨at fur¨ Mathematik, Informatik und Naturwissenschaften der RWTH Aachen University zur Erlangung des akademischen Grades einer Doktorin der Naturwissenschaften genehmigte Dissertation vorgelegt von Diplom-Biologin Laura Huth (geb. Franken) aus Julich¨ Berichter: Universit¨atsprofessor Dr. rer. nat. Edgar Dahl Universit¨atsprofessor Dr. rer. nat. Ralph Panstruga Tag der mundlichen¨ Prufung:¨ 6. August 2014 Diese Dissertation ist auf den Internetseiten der Hochschulbibliothek online verfugbar.¨ Zusammenfassung Krebserkrankungen stellen weltweit eine der h¨aufigsten Todesursachen dar. Aus diesem Grund ist die Aufkl¨arung der zugrunde liegenden Mechanismen und Ur- sachen ein essentielles Ziel der molekularen Onkologie. Die Tumorforschung der letzten Jahre hat gezeigt, dass die Entstehung solider Karzinome ein Mehrstufen- Prozess ist, bei dem neben Onkogenen auch Tumorsuppresorgene eine entschei- dende Rolle spielen. Viele der heute bekannten Gene des WNT-Signalweges wur- den bereits als Onkogene oder Tumorsuppressorgene charakterisiert. Eine Dere- gulation des WNT-Signalweges wird daher mit der Entstehung und Progression vieler humaner Tumorentit¨aten wie beispielsweise auch dem Mammakarzinom, der weltweit h¨aufigsten Krebserkrankung der Frau, assoziiert. SFRP1, ein nega- tiver Regulator der WNT-Signalkaskade, wird in Brusttumoren haupts¨achlich durch den epigenetischen Mechanismus der Promotorhypermethylierung
    [Show full text]
  • Cannabinoid CB1R Receptor Mediates Metabolic Syndrome in Models of Circadian and Glucocorticoid Dysregulation Nicole Bowles
    Rockefeller University Digital Commons @ RU Student Theses and Dissertations 2013 Cannabinoid CB1R Receptor Mediates Metabolic Syndrome in Models of Circadian and Glucocorticoid Dysregulation Nicole Bowles Follow this and additional works at: http://digitalcommons.rockefeller.edu/ student_theses_and_dissertations Part of the Life Sciences Commons Recommended Citation Bowles, Nicole, "Cannabinoid CB1R Receptor Mediates Metabolic Syndrome in Models of Circadian and Glucocorticoid Dysregulation" (2013). Student Theses and Dissertations. Paper 232. This Thesis is brought to you for free and open access by Digital Commons @ RU. It has been accepted for inclusion in Student Theses and Dissertations by an authorized administrator of Digital Commons @ RU. For more information, please contact [email protected]. CANNABINOID CB1R RECEPTOR MEDIATES METABOLIC SYNDROME IN MODELS OF CIRCADIAN AND GLUCOCORTICOID DYSREGULATION A Thesis Presented to the Faculty of The Rockefeller University in Partial Fulfillment of the Requirements for the degree of Doctor of Philosophy by Nicole Bowles June 2013 Copyright by Nicole Bowles 2013 CANNABINOID CB1R RECEPTOR MEDIATES METABOLIC SYNDROME IN MODELS OF CIRCADIAN AND GLUCOCORTICOID DYSREGULATION Nicole Bowles, Ph.D. The Rockefeller University 2013 The most recent projections in the growing obesity rates across the nation show an increase to 60% by the year 2030. These growing rates of obesity are paralleled by an increased rates of depressive conditions, anxiety, and sleep loss, often with environmental factors at the root of the cause. Stress and the stress response is a dynamic system that reflects one’s ability to cope with events, behaviorally or physiologically, as stressors occur over a lifetime. While many key players mediate the effects of stress exposure on disease outcomes including the sympathetic nervous system, parasympathetic, inflammatory cytokines and metabolic hormones, this dissertation focuses on glucocorticoids because of the extensive regulatory role they play in mounting the adaptative response to stress.
    [Show full text]
  • List of Approved Ndas for Biological Products That Were Deemed to Be Blas on March 23, 2020
    List of Approved NDAs for Biological Products That Were Deemed to be BLAs on March 23, 2020 On March 23, 2020, an approved application for a biological product under section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) was deemed to be a license for the biological product under section 351 of the Public Health Service Act (PHS Act) (see section 7002(e)(4)(A) of the Biologics Price Competition and Innovation Act of 2009). To enhance transparency and facilitate planning for the March 23, 2020, transition date, FDA compiled a preliminary list of approved applications for biological products under the FD&C Act that were listed in FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book) and that would be affected by this transition provision. FDA posted this list on the FDA website in December 2018, and periodically updated this list before the March 23, 2020, transition date. The September 2019 update to this preliminary list added certain administratively closed applications related to approved applications for biological products that were on the December 2018 version of this list. The January 2020 update to the preliminary list reflected a change to the definition of “biological product” made by the Further Consolidated Appropriations Act, 2020, which was enacted on December 20, 2019. Section 605 of this Act further amended the definition of a “biological product” in section 351(i) of the PHS Act to remove the parenthetical “(except any chemically synthesized polypeptide)” from the statutory category of “protein.” FDA has provided below a list of each approved application for a biological product under the FD&C Act that was deemed to be a license (i.e., an approved biologics license application (BLA)) for the biological product on March 23, 2020.
    [Show full text]
  • Disrupted Blood-Retina Lysophosphatidylcholine Transport
    Research Articles: Cellular/Molecular Disrupted blood-retina lysophosphatidylcholine transport impairs photoreceptor health but not visual signal transduction https://doi.org/10.1523/JNEUROSCI.1142-19.2019 Cite as: J. Neurosci 2019; 10.1523/JNEUROSCI.1142-19.2019 Received: 16 May 2019 Revised: 4 October 2019 Accepted: 23 October 2019 This Early Release article has been peer-reviewed and accepted, but has not been through the composition and copyediting processes. The final version may differ slightly in style or formatting and will contain links to any extended data. Alerts: Sign up at www.jneurosci.org/alerts to receive customized email alerts when the fully formatted version of this article is published. Copyright © 2019 the authors 1 Disrupted blood-retina lysophosphatidylcholine transport impairs 2 photoreceptor health but not visual signal transduction 3 4 Abbreviated title (50 characters): Photoreceptor function under DHA deprivation 5 6 Ekaterina S. Lobanova1,2*, Kai Schuhmann3, Stella Finkelstein4, Tylor R. Lewis4, Martha 7 A. Cady4, Ying Hao4, Casey Keuthan1,5, John D. Ash1,5, Marie E. Burns6, Andrej 8 Shevchenko3, and Vadim Y. Arshavsky4,7* 9 1Department of Ophthalmology, University of Florida, Gainesville, FL, 32610 10 2Department of Pharmacology and Therapeutics, University of Florida, Gainesville, FL, 32610 11 3Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany, 01307 12 4Department of Ophthalmology, Duke University, Durham, NC, 27710 13 5Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL, 14 32610 15 6Department of Cell Biology and Human Anatomy, University of California-Davis, Davis, CA, 16 95618 17 7Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, 27710 18 19 Send correspondence to Ekaterina Lobanova at [email protected] or Vadim Arshavsky at 20 [email protected].
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Us Anti-Doping Agency
    2019U.S. ANTI-DOPING AGENCY WALLET CARDEXAMPLES OF PROHIBITED AND PERMITTED SUBSTANCES AND METHODS Effective Jan. 1 – Dec. 31, 2019 CATEGORIES OF SUBSTANCES PROHIBITED AT ALL TIMES (IN AND OUT-OF-COMPETITION) • Non-Approved Substances: investigational drugs and pharmaceuticals with no approval by a governmental regulatory health authority for human therapeutic use. • Anabolic Agents: androstenediol, androstenedione, bolasterone, boldenone, clenbuterol, danazol, desoxymethyltestosterone (madol), dehydrochlormethyltestosterone (DHCMT), Prasterone (dehydroepiandrosterone, DHEA , Intrarosa) and its prohormones, drostanolone, epitestosterone, methasterone, methyl-1-testosterone, methyltestosterone (Covaryx, EEMT, Est Estrogens-methyltest DS, Methitest), nandrolone, oxandrolone, prostanozol, Selective Androgen Receptor Modulators (enobosarm, (ostarine, MK-2866), andarine, LGD-4033, RAD-140). stanozolol, testosterone and its metabolites or isomers (Androgel), THG, tibolone, trenbolone, zeranol, zilpaterol, and similar substances. • Beta-2 Agonists: All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Most inhaled beta-2 agonists are prohibited, including arformoterol (Brovana), fenoterol, higenamine (norcoclaurine, Tinospora crispa), indacaterol (Arcapta), levalbuterol (Xopenex), metaproternol (Alupent), orciprenaline, olodaterol (Striverdi), pirbuterol (Maxair), terbutaline (Brethaire), vilanterol (Breo). The only exceptions are albuterol, formoterol, and salmeterol by a metered-dose inhaler when used
    [Show full text]
  • Cellular and Molecular Signatures in the Disease Tissue of Early
    Cellular and Molecular Signatures in the Disease Tissue of Early Rheumatoid Arthritis Stratify Clinical Response to csDMARD-Therapy and Predict Radiographic Progression Frances Humby1,* Myles Lewis1,* Nandhini Ramamoorthi2, Jason Hackney3, Michael Barnes1, Michele Bombardieri1, Francesca Setiadi2, Stephen Kelly1, Fabiola Bene1, Maria di Cicco1, Sudeh Riahi1, Vidalba Rocher-Ros1, Nora Ng1, Ilias Lazorou1, Rebecca E. Hands1, Desiree van der Heijde4, Robert Landewé5, Annette van der Helm-van Mil4, Alberto Cauli6, Iain B. McInnes7, Christopher D. Buckley8, Ernest Choy9, Peter Taylor10, Michael J. Townsend2 & Costantino Pitzalis1 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Departments of 2Biomarker Discovery OMNI, 3Bioinformatics and Computational Biology, Genentech Research and Early Development, South San Francisco, California 94080 USA 4Department of Rheumatology, Leiden University Medical Center, The Netherlands 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands 6Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy 7Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK 8Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham B15 2WB, UK 9Institute of
    [Show full text]
  • WO 2015/130968 A2 3 September 2015 (03.09.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/130968 A2 3 September 2015 (03.09.2015) P O P C T (51) International Patent Classification: Inc., 75 Francis Street, Boston, MA 021 15 (US). YOSEF, C12Q 1/68 (2006.01) Nir; 1520 Laurel Ave., Richmond, CA 94805 (US). (21) International Application Number: (74) Agents: KOWALSKI, Thomas J. et al; Vedder Price PCT/US20 15/0 17826 P.C., 1633 Broadway, New York, NY 1001 9 (US). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 26 February 2015 (26.02.2015) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (25) Filing Language: English BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (26) Publication Language: English DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (30) Priority Data: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, 61/945,641 27 February 2014 (27.02.2014) US MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (71) Applicants: THE BROAD INSTITUTE INC. [US/US]; PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 415 Main Street, Cambridge, MA 02142 (US). THE SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, BRIGHAM AND WOMEN'S HOSPITAL, INC.
    [Show full text]
  • Anti-Inflammatory Role of Curcumin in LPS Treated A549 Cells at Global Proteome Level and on Mycobacterial Infection
    Anti-inflammatory Role of Curcumin in LPS Treated A549 cells at Global Proteome level and on Mycobacterial infection. Suchita Singh1,+, Rakesh Arya2,3,+, Rhishikesh R Bargaje1, Mrinal Kumar Das2,4, Subia Akram2, Hossain Md. Faruquee2,5, Rajendra Kumar Behera3, Ranjan Kumar Nanda2,*, Anurag Agrawal1 1Center of Excellence for Translational Research in Asthma and Lung Disease, CSIR- Institute of Genomics and Integrative Biology, New Delhi, 110025, India. 2Translational Health Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, 110067, India. 3School of Life Sciences, Sambalpur University, Jyoti Vihar, Sambalpur, Orissa, 768019, India. 4Department of Respiratory Sciences, #211, Maurice Shock Building, University of Leicester, LE1 9HN 5Department of Biotechnology and Genetic Engineering, Islamic University, Kushtia- 7003, Bangladesh. +Contributed equally for this work. S-1 70 G1 S 60 G2/M 50 40 30 % of cells 20 10 0 CURI LPSI LPSCUR Figure S1: Effect of curcumin and/or LPS treatment on A549 cell viability A549 cells were treated with curcumin (10 µM) and/or LPS or 1 µg/ml for the indicated times and after fixation were stained with propidium iodide and Annexin V-FITC. The DNA contents were determined by flow cytometry to calculate percentage of cells present in each phase of the cell cycle (G1, S and G2/M) using Flowing analysis software. S-2 Figure S2: Total proteins identified in all the three experiments and their distribution betwee curcumin and/or LPS treated conditions. The proteins showing differential expressions (log2 fold change≥2) in these experiments were presented in the venn diagram and certain number of proteins are common in all three experiments.
    [Show full text]
  • Ginger and Turmeric Expressed Sequence Tags Identify Signature
    Ginger and turmeric expressed sequence tags identify signature genes for rhizome identity and development and the biosynthesis of curcuminoids, gingerols and terpenoids Koo et al. Koo et al. BMC Plant Biology 2013, 13:27 http://www.biomedcentral.com/1471-2229/13/27 Koo et al. BMC Plant Biology 2013, 13:27 http://www.biomedcentral.com/1471-2229/13/27 RESEARCH ARTICLE Open Access Ginger and turmeric expressed sequence tags identify signature genes for rhizome identity and development and the biosynthesis of curcuminoids, gingerols and terpenoids Hyun Jo Koo1,6†, Eric T McDowell1†, Xiaoqiang Ma1,7†, Kevin A Greer2,8, Jeremy Kapteyn1, Zhengzhi Xie1,3,9, Anne Descour2, HyeRan Kim1,4,10, Yeisoo Yu1,4, David Kudrna1,4, Rod A Wing1,4, Carol A Soderlund2 and David R Gang1,5,11* Abstract Background: Ginger (Zingiber officinale) and turmeric (Curcuma longa) accumulate important pharmacologically active metabolites at high levels in their rhizomes. Despite their importance, relatively little is known regarding gene expression in the rhizomes of ginger and turmeric. Results: In order to identify rhizome-enriched genes and genes encoding specialized metabolism enzymes and pathway regulators, we evaluated an assembled collection of expressed sequence tags (ESTs) from eight different ginger and turmeric tissues. Comparisons to publicly available sorghum rhizome ESTs revealed a total of 777 gene transcripts expressed in ginger/turmeric and sorghum rhizomes but apparently absent from other tissues. The list of rhizome-specific transcripts was enriched for genes associated with regulation of tissue growth, development, and transcription. In particular, transcripts for ethylene response factors and AUX/IAA proteins appeared to accumulate in patterns mirroring results from previous studies regarding rhizome growth responses to exogenous applications of auxin and ethylene.
    [Show full text]